VPTDF - Ventripoint Provides Corporate Update on Sales and Marketing
(via TheNewswire)
Toronto, Ontario / TheNewswire / August 1, 2018 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT) is pleased to present an update on its progress to provide better tools for cardiac analysis to cardiologists to improve diagnosis and treatment of heart disease.
Completed and Pending Installations of the VMS+ Whole-Heart Analysis System
The Company has installed the first VMS+ in Edmonton at the University of Alberta Mazankowski Alberta Heart Institute, where it is being used with oncology patients, who require contrast-enhanced ultrasound imaging. It is also being employed on women with normal and high-risk pregnancies.
About the Mazankowski Alberta Heart Institute (Mazankowski)
Mazankowski is the advanced cardiac care center for Edmonton, Northern and North-Central Alberta, Northern BC, Saskatchewan, Manitoba, Yukon and Northwest Territories. Located on the Walter C. Mackenzie Health Sciences Centre Campus in Edmonton, Mazankowski is physically integrated with the University of Alberta and Stollery Children's Hospitals, making it one of the very few heart institutes to accommodate both adult and pediatric patients. The Mazankowski has one of the most technologically advanced Echo Labs in the world providing leading-edge imaging techniques such as 3D, contrast, myocardial perfusion, speckle tracking and interventional echo.
A second machine will be installed at MD Anderson Hospital in a few weeks and will be used for routine clinical assessment of oncology patients to determine cardiac changes during and after treatments.
About MD Anderson Cancer Center
MD Anderson has been one of the top two cancer centers in the USA for decades. It receives the highest number of research grants from the National Cancer Institute and is the recognized leader in the diagnosis and treatment of cancer. The hospital sees approximately 1.5 million patients a year and performed 575,000 imaging exams in 2017.
Pending Sales
The Company has 5 pending sales where the cardiology department has an approved budget to purchase the VMS+ and the Company is awaiting a purchase order. Each of these new users are recognized leaders in cardiac care and will be using the VMS+ for routine applications as well as research into expanding the application of the VMS+ to inform the best treatment path to be taken for each patient.
Ongoing Marketing Efforts
The Company exhibited at the Annual Canadian Society of Echocardiography Weekend from April 12-14, 2018 in Toronto, and the American Society for Echocardiography annual conference, June 22-26, 2018 in Nashville, Tennessee, and identified a number of potential customers. The conferences had a combined attendance of 3,000 attendees from almost 50 countries. The sales team is following up with these contacts and reaching out to 300 clinical centers, which have a profile of patients where the VMS+ would provide significant benefits to their cardiac service. Capital purchases require a long process for budget approval, as well as signoff by a number of hospital departments, such as bioengineering and IT, before a purchase order is generated.
Annual General Meeting
The Company will hold its Annual General Meeting on August 13th at its corporate offices in Toronto. More details are included in the circular, which has been mailed to shareholders of record.
About Ventripoint Diagnostics Ltd.
Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
For further information please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.